[Thrombosis with Thrombocytopenia Syndrome following adenovirus vector-based vaccines to prevent COVID-19: epidemiology and clinical presentation in Spain].

ABSTRACT:

Background

We describe the epidemiological and clinical characteristics of thrombosis with thrombocytopenia syndrome (TTS) cases reported in Spain.

Methods

We included all venous or arterial thrombosis with thrombocytopenia following adenovirus vector-based vaccines (AstraZeneca or Janssen) to prevent COVID-19 disease between February 1^st and September 26^th, 2021. We describe the crude rate and the standardized morbidity ratio. We assessed the predictors of mortality.

Results

Sixty-one cases were reported and 45 fulfilled eligibility criteria, 82% women. The crude TTS rate was 4/1,000,000 doses and 14-15/1,000,000 doses between 30-49 years. The number of observed cases of cerebral venous thrombosis was 6-18 higher than the expected in patients yo

SUBMITTER: Garcia-Azorin D 

PROVIDER: S-EPMC9124923 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature